PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Kara Mayes, MD, FAAFP / Jay H. Shubrook, DO, FAAFP, FACOFP - Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals Aug 31, 2023

Show notes

Go online to PeerView.com/PQU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox! Upon completion of this activity, participants should be better able to: Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications; Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management; and Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority.

R. Scott Wright, MD - When Statins Strike Out: Using PCSK9-Targeting Strategies to Achieve Lipid Goals and Reduce Cardiovascular Risks in Patients With Hyperlipidemia Aug 30, 2023

Show notes

Go online to PeerView.com/EEG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple professional societies have emphasized the importance of lowering LDL-C for the primary and secondary prevention of ASCVD and cardiovascular events. Though current guidelines recommend statins as the cornerstone of lipid-lowering therapies, many patients have insufficient response or intolerance to them and require non-statin therapies to achieve their individualized LDL-C goals. Enter PCSK9-targeting therapies! This CME activity shares current gaps in hyperlipidemia care, offers strategies for meeting these unmet needs, and presents the latest clinical data for PCSK9-targeting agents. An in-depth patient case example helps to illustrate the importance of screening and ASCVD risk assessment, how to initiate therapy with novel strategies, and best practices for improving hyperlipidemia management to help more patients achieve their goals. Upon completion of this activity, participants should be better able to: Incorporate evidence-based, guideline-compliant strategies into the management of hyperlipidemia to prevent primary and secondary cardiovascular events, especially in patients who are statin intolerant or already using the maximally tolerated statin dosage; Recognize the differences among PCSK9-targeting agents and other classes of lipid-lowering therapies for managing hyperlipidemia in individuals at high risk of ASCVD with regard to mechanisms of action, cardiovascular outcomes, and the latest clinical evidence; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for PCSK9-targeting therapies.

Stephen P. Salloway, MD, MS - Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA) Aug 24, 2023

Show notes

Go online to PeerView.com/QVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. After almost two decades without a new AD treatment, recent advances in disease-modifying therapies—including the accelerated FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have introduced the possibility of slowed disease progression and improved patient outcomes. Furthermore, significant advances have been made in identifying and testing biomarkers for AD that may aid in early diagnosis, proper treatment selection, and assessment of therapeutic response. The latter is increasingly important given the need to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia. With the rapid developments in AD assessment and treatment, it is vitally important to increase awareness of ARIA among healthcare providers. In this activity, based on a recent live symposium, AD experts pair compelling, real-world case scenarios with practice-changing evidence to illustrate how to select patients for treatment with ATTs, how to discuss the risk of ARIA with patients, and how to monitor, recognize, and manage ARIA in patients once they start treatment. Upon completion of this activity, participants should be better able to: Select appropriate patients for treatment with amyloid-targeting therapies (ATTs); Appropriately monitor for and manage amyloid-related imaging abnormalities (ARIA) in patients taking ATTs for the treatment of early-stage Alzheimer’s disease (AD); and Implement effective communication strategies to educate patients and caregivers about ARIA.

David J. Kuter, MD, DPhil / Cindy Neunert, MD, MSCS - New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes Aug 22, 2023

Show notes

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.

Jennifer Woyach, MD - Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy Aug 21, 2023

Show notes

Go online to PeerView.com/UTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care. Upon completion of this activity, participants should be better able to: Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance; Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions; Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors; and Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies.

Bradley S. Miller, MD, PhD - Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies Aug 11, 2023

Show notes

Go online to PeerView.com/ZAB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of recombinant human growth hormone (rhGH) therapy has facilitated wider treatment of growth hormone deficiency. In this CME-certified MasterClass & Practicum video activity, expert faculty will review current guidelines for pediatric growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. Tune in today to increase your knowledge and competence on the diagnosis and management of growth hormone deficiency with rhGH therapy, including long-acting growth hormone agents, and gain a better understanding of how to address patient needs. Upon completion of this activity, participants should be better able to: Utilize relevant diagnostic tests to provide timely diagnosis of pediatric patients suspected to have growth hormone deficiency; Compare the clinical characteristics and supporting evidence (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) for various options in growth hormone therapy; and Incorporate growth hormone therapy into personalized management plans to address pediatric patient challenges such as dosage concerns, administration, adherence, and monitoring.

Mark J. Levis, MD, PhD - Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors Aug 11, 2023

Show notes

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors Aug 11, 2023

Show notes

Go online to PeerView.com/MVQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials. Upon completion of this activity, participants should be better able to: Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors; Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs; and Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation.

Philip Harvey, PhD - Visualizing a New Horizon: Emerging Advances in the Treatment of Cognitive Impairment Associated With Schizophrenia Aug 07, 2023

Show notes

Go online to PeerView.com/FMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore recent advances in the management of cognitive impairment associated with schizophrenia (CIAS) and learn how to implement current and emerging treatment strategies into individualized care plans to improve your patients’ outcomes and quality of life. Upon completion of this activity, participants should be better able to: Summarize the burdens of cognitive impairment in patients with schizophrenia and its impact on patient outcomes and quality of life; Describe the pathophysiology of CIAS, emphasizing the difference between negative symptoms and cognitive impairment; and Implement current and emerging treatment strategies for CIAS, taking into account the latest evidence and patient treatment goals, preferences, and unmet needs.

Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics Aug 07, 2023

Show notes

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected